Karyopharm announces further transition of co-founders sharon shacham phd, mba and michael kauffman, md, phd and appointment of reshma rangwala, md, phd as chief medical officer

- formerly of aravive, genmab and merck & co., dr. rangwala will lead karyopharm's clinical development programs and strategy - - as part of karyopharm's evolution, co-founders dr. shacham and dr. kauffman will transition out of the company on may 31, 2022 -  - dr. shacham will continue her engagement with the company's scientific advisory board and serve in an advisory capacity - newton, mass. , march 29, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of reshma rangwala, md, phd, as the company's chief medical officer.
KPTI Ratings Summary
KPTI Quant Ranking